Literature DB >> 26481868

Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.

Chun-Ming Wong1, Lai Wei1, Cheuk-Ting Law1, Daniel Wai-Hung Ho1, Felice Ho-Ching Tsang1, Sandy Leung-Kuen Au1, Karen Man-Fong Sze1, Joyce Man-Fong Lee1, Carmen Chak-Lui Wong1, Irene Oi-Lin Ng1.   

Abstract

UNLABELLED: Epigenetic deregulation plays an important role in liver carcinogenesis. Using transcriptome sequencing, we examined the expression of 591 epigenetic regulators in hepatitis B-associated human hepatocellular carcinoma (HCC). We found that aberrant expression of epigenetic regulators was a common event in HCC. We further identified SETDB1 (SET domain, bifurcated 1), an H3K9-specific histone methyltransferase, as the most significantly up-regulated epigenetic regulator in human HCCs. Up-regulation of SETDB1 was significantly associated with HCC disease progression, cancer aggressiveness, and poorer prognosis of HCC patients. Functionally, we showed that knockdown of SETDB1 reduced HCC cell proliferation in vitro and suppressed orthotopic tumorigenicity in vivo. Inactivation of SETDB1 also impeded HCC cell migration and abolished lung metastasis in nude mice. Interestingly, SETDB1 protein was consistently up-regulated in all metastatic foci found in different organs, suggesting that SETDB1 was essential for HCC metastatic progression. Mechanistically, we showed that the frequent up-regulation of SETDB1 in human HCC was attributed to the recurrent SETDB1 gene copy gain at chromosome 1q21. In addition, hyperactivation of specificity protein 1 transcription factor in HCC enhanced SETDB1 expression at the transcriptional level. Furthermore, we identified miR-29 as a negative regulator of SETDB1. Down-regulation of miR-29 expression in human HCC contributed to SETDB1 up-regulation by relieving its post-transcriptional regulation.
CONCLUSION: SETDB1 is an oncogene that is frequently up-regulated in human HCCs; the multiplicity of SETDB1 activating mechanisms at the chromosomal, transcriptional, and posttranscriptional levels together facilitates SETDB1 up-regulation in human HCC.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26481868     DOI: 10.1002/hep.28304

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  A drive in SUVs: From development to disease.

Authors:  Vinay Kumar Rao; Ananya Pal; Reshma Taneja
Journal:  Epigenetics       Date:  2017-01-20       Impact factor: 4.528

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.

Authors:  James Ropa; Nirmalya Saha; Hsiangyu Hu; Luke F Peterson; Moshe Talpaz; Andrew G Muntean
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

Review 6.  A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.

Authors:  Craig L Parfett; Daniel Desaulniers
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

Review 7.  Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Authors:  Kamakoti P Bhat; H Ümit Kaniskan; Jian Jin; Or Gozani
Journal:  Nat Rev Drug Discov       Date:  2021-01-19       Impact factor: 84.694

Review 8.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

9.  Low H3K9me3 Expression Is Associated With Poor Prognosis in Patients With Distal Common Bile Duct Cancer.

Authors:  Han Gyeol Kim; Ji-Youn Sung; Kiyong Na; So-Woon Kim
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

10.  Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma.

Authors:  Melina Mitsiogianni; Ioannis Anestopoulos; Sotiris Kyriakou; Dimitrios T Trafalis; Rodrigo Franco; Aglaia Pappa; Mihalis I Panayiotidis
Journal:  Invest New Drugs       Date:  2021-05-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.